

Femarelle®

Rejuvenate

INTENDED USE:

Femarelle® Rejuvenate is intended for women 40+ for the management of mood, skin, hair & fatigue associated with the decline in estrogen levels that depicts the time period during which a woman's body makes its natural transition toward the end of menstruation.

WHY IS FEMARELLE® REJUVENATE RIGHT FOR YOU?

Studies have shown that Femarelle® Rejuvenate assists with the overall sense of well-being, assist with energy levels and mood swings within the first month of use.

WHAT IS FEMARELLE® REJUVENATE?

Femarelle® Rejuvenate comprises a unique formulation that includes the proprietary fermented soy derivative (DT56a), flaxseed, vitamin B2 and Biotin (vitamin B7). These compounds contribute to normal energy-yielding metabolism, nervous system function and the maintenance of normal skin. Furthermore, they assist in the maintenance of normal hair and contribute to the reduction of tiredness and fatigue.

Femarelle® Rejuvenate is produced by employing a unique manufacturing procedure without using any harsh chemicals during the production process. The proprietary soy extract of DT56a uses the whole soy compound without extracting any single component. This unique method increases the bio-availability of the active components that are found in Femarelle® Rejuvenate.

Femarelle® Rejuvenate contains no estrogen and is not an isoflavone isolate.

WHY ARE YOU SUFFERING FROM THESE SYMPTOMS?

When a woman reaches her early forties, there are fewer ovarian follicles left in the ovaries. As a result, ovulation occurs less frequently, leading to menstrual irregularity. Because the follicles produce most of the estrogen in the body, estrogen levels also begin to decline. In this transition period between a woman's reproductive years and the time when menstruation ceases completely, hormone levels fluctuate and decline, often at an irregular pace contributing substantially to the sense of physical, mental, and emotional imbalance. The symptoms are sometimes similar to what was felt during PMS (pre-menstrual syndrome), however, they can become longer and more severe in this stage.

Mood swings, a sense of lack of energy, sleep disturbance, skin dryness and hair loss are only a few of the symptoms that are associated with the

decline in estrogen levels, although symptoms vary from woman to woman, the overall feeling is of a decline in the quality of life.

RECOMMENDED INTAKE:

Femarelle® Rejuvenate should be taken twice a day, one capsule in the morning and one in the evening. Swallow the capsule with some water. Femarelle® Rejuvenate can be taken with or without food. It is important that you take two capsules a day as this is the required dose for optimal benefit.

If a dose is missed, one capsule should be taken as soon as possible and the regular schedule should then be continued. There is no need to take a double dose to make up for a missed dose.

COMPOSITION:

Each capsule contains:

DT56a- Glycine Max (Fermented SOYBEAN extract)	322 mg
Capsule (Bovine gelatin- BSE/ TSE free)	97mg
Linum usitatissimum (Ground roasted flaxseed)	50mg
Vitamin B ₂ (Riboflavin)	1 mg
D-Biotin (Vitamin B ₇)	100 µg

CAUTION:

Please note that supplements should not be used as a substitute for a varied diet and healthy lifestyle. As with other supplements, if you have any condition requiring medical attention or are taking prescribed drugs, consult your doctor before taking this product. Not for use during pregnancy, breastfeeding or for children under 12.

ADVERSE REACTIONS:

No significant adverse reactions have been reported to date. However, along with its desired effects, any product may have some unwanted effects, these effects were found to be transient and disappeared once the product was discontinued. Your healthcare practitioner should be informed as soon as possible if you feel unwell while using this product.

Femarelle®

Rejuvenate

STORAGE:

Store in a cool and dry place (room temperature- do not exceed 30°C). Even if kept in their original container and stored as recommended, health products may be kept for a limited period only. Please note that you can't use it beyond the expiry date written on the blister pack. Do not store different medications in the same package. Keep out of reach of children.

MANUFACTURER:

Se-cure Pharmaceuticals Ltd., Dalton Industrial Area, 1381100, Israel

References:

1. Yoles I. et al. Efficacy and Safety of Standard versus Low Dose of Femarelle (Tofupill) for the Treatment of Menopausal Symptoms. *J. of Clin Exper Obstet Gynecol* 2004; 31(2):123-26
2. Labos G., Trakakis E. et al Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women. *J Endocrinol. Invest.* 2013; 36(7):521-6
3. Genazzani AR et al. Brain region responsiveness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats. *Menopause* 2009; 16(5):1037-43
4. Nachtigall M. et al. A Prospective Study of DT56a (Femarelle) for the Treatment of Postmenopausal Vaginal Atrophy. *Menopause* book of abstract of the NAMS 22nd Annual Meeting, Sept, 2011, p. 55
5. Yoles I. et al. Tofupill/Femarelle (DT56a) - a New Phyto-Selective Estrogen Receptor Modulator-like Substance for the Treatment of Postmenopausal Bone Loss. *Menopause* 2003; 10(6):522-25
6. Somjen D, Yoles I. DT56a (Tofupill/Femarelle), selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. *J. of Steroid Biochemistry & Molecular Biology* 2003; 86(1):93-98
7. Somjen D. et al. DT56a (Femarelle/Tofupill) Stimulates Bone Formation in Female Rats. *British J. of Obstetrics & Gynecology* 2005; 112(7):981-85
8. Somjen D., Katzburg S. Lieberherr M., Hendel D., Yoles I. DT56a Stimulates Gender-Specific Human Cultured Bone Cells In Vitro. *J. of Steroid Biochemistry & Molecular Biology* 2006; 98(1):90-96
9. Somjen D. et al. The Effects of Native and Synthetic Estrogenic Compounds as well as Vitamin D Less-Calcemic Analogs on Adipocytes Content in Rat Bone Marrow. *J Endocrinol Invest.* 2011;34(2):106-10
10. Yoles I., and Lilling G. Pharmacological Doses of the Natural

- phyto-SERM DT56a (Femarelle) Have no Effect on MCF-7 Breast Cancer Cell-Line. *European J. of Obstetrics & Gynecology & Reproductive Biology* 2006; 130(1):140-141
11. Nachtigall M et al. The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women. *Menopause* 2011;18(3):285-288
 12. Oropeza M.V, Orozco S, Ponce H, Campos M.G. Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract. *Reproductive Toxicology* 2005; 20(2):261-66
 13. Somjen D, Yoles I. DT56a (Femarelle): a Natural Selective Estrogen Receptor Modulator (SERM). *J. of Steroid Biochemistry & Molecular Biology* 2007;104:252-58
 14. Somjen D. et al. DT56a (Femarelle); contrary to estradiol-17 β ; is effective in human derived female osteoblasts in hyperglycemic condition. *J Steroid Biochem Mol Biol.* 2011; 123:25-29
 15. Bedell S., Nachtigall M., Naftolin F. The pros and cons of plant estrogens for menopause; *J. Steroid Biochem. Mol. Biol.* 2014;139:225-236
 16. Sánchez-Borrego R, Mendoza N, Llana P. A prospective study of DT56a (Femarelle) for the treatment of menopause symptoms. *Climacteric.* 2015;18(6):813-6
 17. Sánchez-Borrego R. et al. Efficacy and safety of a phyto-SERM as an alternative to hormone therapy; *Climacteric.* 2015 Jun;18(3):350-7
 18. Chen FP et al. Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: An open label trial. *Taiwan J Obstet Gynecol.* 2016 Jun; 55(3):336-40
 19. Somjen D, Yoles I.: "DT56a stimulates creatine kinase specific activity in vascular tissues of rats. *J. of Endocrinological Investigation* 2003;26(10):966-971
 20. Somjen D. et al. Interaction between the effects of the selective estrogen modulator Femarelle and a vitamin D analog in human umbilical artery vascular smooth muscle cells. *J Steroid Biochem Mol Biol.* 2017;174:9-13
 21. Genazzani AR. DT56a, a non-hormonal botanical therapy, as first line treatment for menopausal symptoms. *12th European Society of Gynecology Congress*, Opening Symposium - Climacteric and Menopause: from symptoms to therapies, from security to efficacy; October 18, 2017

In order to view the articles please insert Femarelle when entering pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/>

We, at Se-cure Pharmaceuticals Ltd, are constantly investing in bringing you as much information regarding the benefits that Femarelle® Rejuvenate can provide you.

You can follow us on: 